RxDoctor Payments Data

Bryan Krull, DO

Nephrology · Brunswick, GANPI 1649296682

Payments from drug & device makers

$8,841in general payments, 2019–2025

Across 453 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$1K
  • AstraZeneca$1K
  • Amgen$919
  • Otsuka America Pharmaceutical, Inc.$770
  • Ardelyx, Inc.$541
  • Travere Therapeutics, Inc.$415
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,39595%
  • Education$4455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,841 in reported general payments places this provider in the 80th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$218,760
Medicare patients
444
Services billed
1,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$71,220
FarxigaDapagliflozin Propanediol81$60,154
BiktarvyBictegrav/Emtricit/Tenofov Ala12$46,117
OzempicSemaglutide48$45,691
MyrbetriqMirabegron41$30,952
MounjaroTirzepatide29$28,284
JanuviaSitagliptin Phosphate31$23,674
EntrestoSacubitril/Valsartan16$18,121
RybelsusSemaglutide17$16,234
ProcritEpoetin Alfa16$12,806
Janumet XrSitagliptin Phos/Metformin Hcl12$11,695
ClinolipidFat Emulsion/Olive/Soy/Phospho26$5,601
ProsolParenteral Amino Acid 20% No.138$3,959
ClinisolParenteral Amino Acid 15% No.520$3,296
Telmisartan76$3,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$40$71,22071 claims
Novo NordiskOzempic, Rybelsus$65$61,92465 claims
AstraZenecaFarxiga$1,019$60,15481 claims
Astellas Pharma US IncMyrbetriq$17$30,95241 claims
Lilly USA, LLCMounjaro$66$28,28429 claims
NovartisEntresto$317$18,12116 claims
Johnson & JohnsonProcrit$17$12,80616 claims
ANI Pharmaceuticals, Inc.Valsartan$140$1,67157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 388 nephrology providers in Georgia.

Other nephrology in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →